Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone303-703-4906
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$23.43 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Zynex (OTCMKTS:ZYXI) Frequently Asked Questions
What is Zynex's stock symbol?
Zynex trades on the OTCMKTS under the ticker symbol "ZYXI."
How were Zynex's earnings last quarter?
Zynex Inc. (OTCMKTS:ZYXI) released its quarterly earnings results on Wednesday, July, 31st. The company reported $0.06 earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of $0.06. The business earned $10.30 million during the quarter, compared to analyst estimates of $9.84 million. Zynex had a return on equity of 152.81% and a net margin of 33.33%. View Zynex's Earnings History.
What guidance has Zynex issued on next quarter's earnings?
Zynex issued an update on its third quarter 2019 earnings guidance on Wednesday, July, 31st. The company provided EPS guidance of for the period. The company issued revenue guidance of $10.7-11.2 million, compared to the consensus revenue estimate of $10.3 million.
What price target have analysts set for ZYXI?
1 brokers have issued twelve-month price objectives for Zynex's shares. Their forecasts range from $10.75 to $10.75. On average, they expect Zynex's share price to reach $10.75 in the next twelve months. This suggests a possible upside of 14.4% from the stock's current price. View Analyst Price Targets for Zynex.
What is the consensus analysts' recommendation for Zynex?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zynex.
Has Zynex been receiving favorable news coverage?
News stories about ZYXI stock have trended negative on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zynex earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Zynex.
Who are some of Zynex's key competitors?
Some companies that are related to Zynex include Natus Medical (BABY), Natus Medical (NTUS), InMode (INMD), AxoGen (AXGN), TransMedics Group (TMDX), Cutera (CUTR), BioLife Solutions (BLFS), Viewray (VRAY), Stereotaxis (STXS), Semler Scientific (SMLR), Rockwell Medical (RMTI), BioSig Technologies (BSGM), Fonar (FONR), electroCore (ECOR) and Edap Tms (EDAP).
What other stocks do shareholders of Zynex own?
Who are Zynex's key executives?
Zynex's management team includes the folowing people:
- Mr. Thomas Sandgaard, Founder, Pres, CEO & Chairman (Age 60)
- Mr. Daniel J. Moorhead, Chief Financial Officer (Age 47)
- Mr. David B. Mogill, VP of Operations
- Mr. Robert Bird, VP of Marketing
- Mr. Steve Siefring, Director of Bus. Devel.
Who are Zynex's major shareholders?
Zynex's stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.83%), BlackRock Inc. (2.38%), Acadian Asset Management LLC (0.34%), Northern Trust Corp (0.22%), Newman Dignan & Sheerar Inc. (0.12%) and WealthTrust Axiom LLC (0.10%). Company insiders that own Zynex stock include Daniel J Moorhead and Thomas Sandgaard. View Institutional Ownership Trends for Zynex.
Which institutional investors are selling Zynex stock?
ZYXI stock was sold by a variety of institutional investors in the last quarter, including Newman Dignan & Sheerar Inc. and Sigma Planning Corp. Company insiders that have sold Zynex company stock in the last year include Daniel J Moorhead and Thomas Sandgaard. View Insider Buying and Selling for Zynex.
Which institutional investors are buying Zynex stock?
ZYXI stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., Northern Trust Corp, Acadian Asset Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., Wells Fargo & Company MN and Jane Street Group LLC. View Insider Buying and Selling for Zynex.
How do I buy shares of Zynex?
Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Zynex's stock price today?
One share of ZYXI stock can currently be purchased for approximately $9.40.
How big of a company is Zynex?
Zynex has a market capitalization of $305.11 million and generates $23.43 million in revenue each year. The company earns $7.36 million in net income (profit) each year or $0.22 on an earnings per share basis. View Additional Information About Zynex.
What is Zynex's official website?
How can I contact Zynex?
Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303-703-4906 or via email at [email protected]
MarketBeat Community Rating for Zynex (OTCMKTS ZYXI)
MarketBeat's community ratings are surveys of what our community members think about Zynex and other stocks. Vote "Outperform" if you believe ZYXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
